The validity of 18F-GE180 as a TSPO imaging agent

Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1205-1207. doi: 10.1007/s00259-019-4268-4. Epub 2019 Jan 17.
No abstract available

Publication types

  • Letter

MeSH terms

  • Animals
  • Biomarkers / analysis
  • Biopsy
  • Blood-Brain Barrier
  • Brain / diagnostic imaging
  • Brain Neoplasms / diagnostic imaging
  • Carbazoles / chemistry*
  • Fluorine Radioisotopes / chemistry*
  • Fluorodeoxyglucose F18 / chemistry*
  • Genotype
  • Humans
  • Indoles / chemistry*
  • Inflammation / diagnostic imaging
  • Ligands
  • Loperamide / chemistry
  • Multiple Sclerosis / diagnostic imaging
  • Positron-Emission Tomography / methods*
  • Protein Binding
  • Purines / chemistry
  • Receptors, GABA / analysis*
  • Reproducibility of Results
  • Verapamil / chemistry

Substances

  • 18F-GE180
  • Biomarkers
  • Carbazoles
  • Fluorine Radioisotopes
  • GE-180
  • Indoles
  • Ligands
  • N-benzyl-N-ethyl-2-(7,8-dihydro-7-methyl-8-oxo-2-phenyl-9H-purin-9-yl)acetamide
  • Purines
  • Receptors, GABA
  • TSPO protein, human
  • Fluorodeoxyglucose F18
  • Loperamide
  • Verapamil